Clinical trial · Observational
Prescription Opioid Misuse Assessment
Assessment of the Prevalence of Analgesics Opioid Misuse in Chronic Non-cancer Pain Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chronic pain is a worldwide health problem due to its high prevalence and its difficult management with a significant impact on quality of life. Pain and addiction co-occur frequently. Indeed, the prevalence of addiction in patients with chronic non-cancer pain may affect from 0% to 50% of patients (Højsted et al 2010). This large variability in the estimation of addiction prevalence in chronic non-cancer pain patients is at least partly due to a lack of standardization of the selected patients from the clinical or therapeutic point of view and the lack of consensus in the use of a specific evaluation tool or gold standard. Indeed, several tools are currently available at the international level with varying efficiencies and precisions (Chou et al 2009, Turk, Swanson, and Gatchel 2008, Højsted and Sjøgren 2007). In France, no data are available on the prevalence of analgesic opioid misuse in chronic non-cancer pain patients, due to the lack clinical studies and validated tools in French.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prescription Opioid Misus Index | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with chronic non-cancer pain
- description
- Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
- interventionNames
- Other: Prescription Opioid Misus Index
Primary outcomes (1)
- measure
- Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale
- timeFrame
- at day 1
- description
- A score ≥ 2 is considered positive and will define a misuse behavior
Secondary outcomes (2)
- measure
- Analgesic opioids used by the patient will be collected in the questionnaire
- timeFrame
- at day 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Patients (male or female) ≥ 18 years old * Patients with chronic non-cancer pain for at least 6 months * Patients treated with analgesic opioids for at least 3 months Exclusion Criteria: * Patients (male or female) \< 18 years old * Patients with chronic pain for less than 6 months * Patients with cancer pain * Patients treated with analgesic opioids for less than 3 months
References
Publications (1)
- DERIVEDKerckhove N, Delage N, Bertin C, Kuhn E, Cantagrel N, Vigneau C, Delorme J, Lambert C, Pereira B, Chenaf C, Authier N; Poma Network. Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale. Front Pharmacol. 2022 Sep 5;13:947006. doi: 10.3389/fphar.2022.947006. eCollection 2022. PMID 36133827